Site search
3023 results for '' found
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naï
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naï
/
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (NCT07015190)
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (NCT07015190)
/
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled, 3-Part Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Doses of TRB-061 in Healt
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled, 3-Part Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Doses of TRB-061 in Healt
/
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin [NKTR-358] Monotherapy in the Treatment of Patients = 12 Years of
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin [NKTR-358] Monotherapy in the Treatment of Patients = 12 Years of
/
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persist
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persist
/
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered A
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered A
/
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium [177Lu] vipivotide tetraxetan [AAA617] in combination with an androgen receptor pathway inhibitor
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium [177Lu] vipivotide tetraxetan [AAA617] in combination with an androgen receptor pathway inhibitor
/
A Phase 1/2 Study of CLIO-8221 in Patients with Advanced Solid Tumors (NCT07300943)
A Phase 1/2 Study of CLIO-8221 in Patients with Advanced Solid Tumors (NCT07300943)
/
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma [DAWN-303] (NCT07522073)
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma [DAWN-303] (NCT07522073)
/
The effect of retrograde autologous priming on transfusion requirements after cardiac surgery [TheRAPy]: a multiple period vanguard cluster crossover trial – Australian arm (Trial Not Registered)
The effect of retrograde autologous priming on transfusion requirements after cardiac surgery [TheRAPy]: a multiple period vanguard cluster crossover trial – Australian arm (Trial Not Registered)
/